Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review

doi:10.4239/wjd.v11.i11.553

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8928)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

382

WORD

182

HTML

4217

Figures (1-7)

276

Tables (1-1)

292

Sum=5349

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

427

Download

967

Sum=1394

Publishing Process of This Article

Item

Count

Browse

608

Download

1577

Sum=2185

Nov 15, 2020 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. Nov 15, 2020; 11(11): 553-566
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.553

Table 1 Baseline characteristics of included studies

Ref.	Patients No.	Interventions (dose/d)	Treatment period (wk)	Age mean (SD)	Sex, n (%) female	eGFR [mean (SD) mL/min/1.73 m²]	UACR, mg/g creatinine median (Q1 to Q3) or mean (SD)	SBP, mmHg mean (SD)	DBP, mmHg mean (SD)	Hemoglobin A1c, % mean (SD)	Study type	NCT number
Heerspink et al[12], 2019	2648	Atrasentan 0.75 mg	53 mo? (follow-up 2.2 years)	I: 64.8 (8.6)	25%	44.0 (13.7)	792 (462-1480)	136.5 (15.2)	75.0 (9.9)	7.8 (1.5)	RCT	NCT01858532
Heerspink et al[12], 2019	2648	Atrasentan 0.75 mg	53 mo? (follow-up 2.2 years)	C: 64.7 (8.7)	26.60%	43.7 (13.7)	805 (444-1451)	136.2 (14.8)	74.8 (10.0)	7.8 (1.5)	RCT	NCT01858532
Kohan et al[7], 2011	89	Atrasentan 0.25 mg, 0.75 mg, 1.75 mg	8	I: 63 (12) 67 (9) 64 (13)	41% 36% 27%	31 (4) 34 (6) 33 (5)	350 (194-1226) 360 (209-726) 433 (157-998)	134 (14) 137 (15) 135 (11)	75 (8) 74 (8) 75 (9)	7.6 (1.0) 7.6 (1.2) 7.3 (1.1)	RCT	N/A
Kohan et al[7], 2011	89	Atrasentan 0.25 mg, 0.75 mg, 1.75 mg	8	C: 61 (8)	17%	34 (5)	515 (170-1477)	138 (14)	78 (8)	7.4 (0.9)	RCT	N/A
Mann et al[8], 2010	1392	Avosentan 25, 50 mg	48	I: 61.2 (8.8) 61.0 (9.1)	30.8% 32.8%	29.9 (6.2) 30.4 (6.5)	1422 (728.9-2425.3) 1472 (758.5-2515)	137.1 (13.8) 137.0 (14.3)	77.9 (9.2) 77.5 (8.6)	8.0 (1.5) 8.1 (1.6)	RCT	NCT00120328
Mann et al[8], 2010	1392	Avosentan 25, 50 mg	48	C: 60.8 (8.9)	33.80%	30.1 (6.2)	1531 (794.3-2823.9)	135.4 (15.1)	77.2 (9.5)	8.0 (1.5)	RCT	NCT00120328
Rafnsson et al[13], 2011	28	Bosentan 250 mg	4	I: 62 (8)	18.00%	28.9 (7.4)	415 (681.6)	149 (24)	81 (10)	7.4 (1.1)	RCT	NCT01357109
Rafnsson et al[13], 2011	28	Bosentan 250 mg	4	C: 63 (9)	20.80%	31.5 (4.0)	409 (512.7)	151 (25)	78 (9)	8.0 (1.4)	RCT	NCT01357109
Wenzel et al[14], 2009	286	Avosentan 5, 10, 25, and 50 mg	12	I: 60.8 (10.0) 58.4 (10.0)	34% 30%	31.3 (7.0) 32.2 (5.0)	N/A	N/A	N/A	N/A	RCT	N/A
Wenzel et al[14], 2009	286	Avosentan 5, 10, 25, and 50 mg	12	C: 58.4 (10.0)	13%	30.5 (5.0)	N/A	N/A	N/A	N/A	RCT	N/A
Zeeuw et al[9], 2014	211	Atrasentan 0.75 mg or 1.25 mg	12	I: 65.0 (9.8) 64.5 (8.8)	N/A	N/A	878 (515-1682) 826 (481-1389)	138 (14) 136 (15)	75 (10) 74 (9)	7.5 (1.5) 7.7 (1.4)	RCT	NCT01356849 NCT01424319
Zeeuw et al[9], 2014	211	Atrasentan 0.75 mg or 1.25 mg	12	C: 64.3 (9.0)	N/A	N/A	671 (410-1536)	136 (14)	72 (10)	7.4 (1.3)	RCT	NCT01356849 NCT01424319

N/A: Not applicable; I: Intervening group; C: Control group; eGFR: Estimated glomerular filtration rate; UACR: Urinary albumin-to-creatinine ratio; SD: Standard deviation; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; RCT: Randomized controlled trial; NCT: National clinical trial.

Citation: Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. World J Diabetes 2020; 11(11): 553-566
URL: https://www.wjgnet.com/1948-9358/full/v11/i11/553.htm
DOI: https://dx.doi.org/10.4239/wjd.v11.i11.553